

▼ Antibody ▲ Oligonucleotide ◀ Optical imaging agent ◆ Peptide or protein ★ Polymer ■ Radioligand ● Small molecule

## Steady

In 2024, the US Food and Drug Administration approved 50 novel molecular entities, down slightly from 55 in 2023.

DRUG NAME	ACTIVE INGREDIENT	MARKETER	INDICATION	MECHANISM OF ACTION
▼ <b>Alhemo</b>	Concizumab	Novo Nordisk	Prevention of bleeding episodes in people with hemophilia A and B	Antagonist of endogenous tissue factor pathway inhibitor
● <b>Alyftrek</b>	Vanzacaftor, tezacaftor, and deuterivacaftor	Vertex Pharmaceuticals	Cystic fibrosis	Binders of cystic fibrosis transmembrane conductance regulator (CFTR), and a compound that opens CFTR at the cell surface
▲ <b>Tryngolza</b>	Olezarsen	Ionis Pharmaceuticals	Familial chylomicronemia syndrome	Apolipoprotein C-III messenger RNA inhibitor
● <b>Ensacove</b>	Ensartinib	Xcovery Holdings	Non-small-cell lung cancer	Anaplastic lymphoma kinase inhibitor
● <b>Crenessity</b>	Crinecerfont	Neurocrine Biosciences	Classic congenital adrenal hyperplasia	Selective corticotropin-releasing factor type 1 receptor antagonist
▼ <b>Unloxcyt</b>	Cosibelimab	Checkpoint Therapeutics	Cutaneous squamous cell carcinoma	Human programmed death ligand 1 blocker
▼ <b>Bizengri</b>	Zenocutuzumab	Merus	Non-small-cell lung cancer and pancreatic adenocarcinoma	Human epidermal growth factor receptor 2 and 3 binder
● <b>Iomervu</b>	Iomeprol	Bracco Diagnostics	Imaging of blood vessels and body structures	Opacifier
● <b>Rapiblyk</b>	Landiolol	AOP Orphan Pharmaceuticals	Supraventricular tachycardia	β <sub>1</sub> -adrenoreceptor antagonist
● <b>Attruby</b>	Acoramidis	BridgeBio Pharma	Cardiomyopathy	Transthyretin stabilizer
▼ <b>Ziihera</b>	Zanidatamab	Jazz Pharmaceuticals	HER2-positive biliary tract cancer	Human epidermal growth factor receptor 2 binder
● <b>Revuforj</b>	Revumenib	Syndax Pharmaceuticals	Relapsed or refractory acute leukemia	Menin inhibitor
● <b>Orlynvah</b>	Sulopenem etzadroxil and probenecid	Iterum Therapeutics	Urinary tract infections	Antibacterial and renal tubular inhibitor
▼ <b>Vyloy</b>	Zolbetuximab	Astellas Pharma	Gastric or gastroesophageal junction adenocarcinoma	Claudin 18.2-directed cytolytic antibody
▼ <b>Hympavzi</b>	Marstacimab	Pfizer	Prevention or reduction of bleeding episodes related to hemophilia A or B	Antagonist of tissue factor pathway inhibitor
● <b>Itovebi</b>	Inavolisib	Genentech	Breast cancer	Phosphatidylinositol 3-kinase α inhibitor
■ <b>Flyrcado</b>	Flurpiridaz fluorine-18	GE HealthCare	Evaluation of myocardial ischemia and infarction	Mitochondrial complex 1 inhibitor analog
● <b>Cobenfy</b>	Xanomeline and trospium chloride	Bristol Myers Squibb	Schizophrenia	Muscarinic agonists
● <b>Aqneursa</b>	Levacetylleucine	IntraBio	Niemann-Pick disease type C	Unknown
● <b>Miplyffa</b>	Arimoclomol	Zevra Therapeutics	Niemann-Pick disease type C	Unknown
▼ <b>Ebglyss</b>	Lebrikizumab	Eli Lilly and Company	Atopic dermatitis	Interleukin-13 binder
● <b>Lazcluze</b>	Lazertinib	Janssen Biotech	Non-small-cell lung cancer	Epidermal growth factor receptor inhibitor
▼ <b>Niktimvo</b>	Axatilimab	Incyte	Chronic graft-versus-host disease	Colony-stimulating factor 1 receptor binder
● <b>Livdelzi</b>	Seladelpar	Gilead Sciences	Primary biliary cholangitis	Peroxisome proliferator-activated receptor δ agonist
▼ <b>Nemluvio</b>	Nemolizumab	Galderma Laboratories	Prurigo nodularis	Interleukin-31 receptor subunit α antagonist
◆ <b>Yorvipath</b>	Palopegteriparatide	Ascendis Pharma	Hypoparathyroidism	Parathyroid hormone analog
● <b>Voranigo</b>	Vorasidenib	Servier Pharmaceuticals	Astrocytoma or oligodendroglioma	Isocitrate dehydrogenase 1 and 2 inhibitor
● <b>Leqselvi</b>	Deuruxolitinib	Sun Pharmaceutical Industries	Alopecia areata	Janus kinase inhibitor
▼ <b>Kisunla</b>	Donanemab	Eli Lilly and Company	Alzheimer's disease	Amyloid-β plaque reducer
● <b>Ohtuvayre</b>	Ensifentrine	Verona Pharma	Chronic obstructive pulmonary disease	Phosphodiesterase 3 and 4 inhibitor
▼ <b>Piasky</b>	Crovalimab	Genentech	Paroxysmal nocturnal hemoglobinuria	Complement C5 inhibitor
● <b>Sofdra</b>	Sofpironium	Botanix	Primary axillary hyperhidrosis	Acetylcholine inhibitor
● <b>Iqirvo</b>	Elafibranor	Ipsen Biopharmaceuticals	Primary biliary cholangitis	Peroxisome proliferator-activated receptor agonist
▲ <b>Rytelo</b>	Imetelstat	Geron	Myelodysplastic syndromes	Telomerase inhibitor
▼ <b>Imdelltra</b>	Tarlatamab	Amgen	Small-cell lung cancer	DLL3-directed CD3 T-cell engager
● <b>Xolremdi</b>	Mavoxixafor	X4 Pharmaceuticals	Warts, hypogammaglobulinemia, infections, and myelokathexis syndrome	C-X-C chemokine receptor type 4 antagonist
● <b>Ojemda</b>	Tovorafenib	Day One Biopharmaceuticals	Pediatric low-grade glioma	Type II RAF kinase inhibitor
◆ <b>Anktiva</b>	Nogapendekin alfa inbakicept	ImmunityBio	Bladder cancer	Interleukin-15 receptor agonist
◀ <b>Lumisight</b>	Pegulicianine	Lumicell	Optical imaging of cancerous tissue	Fluorescent signal producer
● <b>Zevtera</b>	Ceftobiprole medocartil sodium	Basilea Pharmaceutica	Bloodstream infections, bacterial infections, and bacterial pneumonia	Antibacterial
● <b>Voydeya</b>	Danicopan	Alexion Pharmaceuticals	Extravascular hemolysis with paroxysmal nocturnal hemoglobinuria	Complement factor D inhibitor
● <b>Vafseo</b>	Vadadustat	Akebia Therapeutics	Anemia due to chronic kidney disease	Hypoxia-inducible factor prolyl hydroxylase inhibitor
◆ <b>Winrevair</b>	Sotatercept	Merck & Co.	Pulmonary arterial hypertension	Inhibitor of activin signaling
● <b>Duvyzat</b>	Givinostat	Italfarmaco	Duchenne muscular dystrophy	Unknown
● <b>Tryvio</b>	Aprocintentan	Idorsia Pharmaceuticals	Hypertension	Endothelin receptor antagonist
● <b>Rezdiffra</b>	Resmetirom	Madrigal Pharmaceuticals	Noncirrhotic nonalcoholic steatohepatitis	Thyroid hormone receptor β agonist
▼ <b>Tevimbra</b>	Tislelizumab	BeiGene	Esophageal squamous cell carcinoma	Programmed cell death protein 1 blocker
◆ <b>Letybo</b>	LetibotulinumtoxinA	Hugel	Improvement of the appearance of moderate to severe glabellar lines	Acetylcholine release inhibitor and neuromuscular blocker
● <b>Exblifep</b>	Cefepime and enmetazobactam	Allegra Therapeutics	Complicated urinary tract infections	Antibacterial and β-lactamase inhibitor
★ <b>Zelsuvmi</b>	Berdazimer	LNHC	Molluscum contagiosum	Unknown

Sources: US Food and Drug Administration, companies. Note: Drugs are shown in reverse chronological order of approval during 2024.